Definium Therapeutics (formerly Mind Medicine / MindMed) is a clinical-stage biopharma developing psychedelic-inspired medicines for brain health disorders. Lead candidate DT120 (lysergide / LSD-based) is in late-stage studies for major depressive disorder and generalized anxiety disorder; DT402 explores related psychiatry indications such as autism spectrum disorder. The company applies rigorous clinical development to compounds historically outside mainstream psychiatry.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -42.7 | — |
| Q3 2025 | 0 | — | -67.3 | — |
| Q4 2025 | 0 | — | -50.4 | — |
| Q1 2026 | 0 | — | -77.1 | — |
| Q2 2026 | 0 | — | -159 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Impinj, Inc. (PI), Xometry, Inc. (XMTR), X-Energy, Inc. (XE), Golar LNG Limited (GLNG), Grifols, S.A. (GRFS), Mercury Systems, Inc. (MRCY)